Effect Measure

Bombs, bullets, billions

An urgent communication from the World Health Organization (WHO) expresses concisely how far behind we are in being prepared for a global pandemic of influenza. Currently there are a number of vaccines under development, some of which might protect against an H5N1 virus that has become readily transmissible from person to person. But none are in production, and even if some were found adequate (not the case) and large scale production begun (far from the case), we, the world, would still be in a fix:

“We are presently several billion doses short of the amount of pandemic influenza vaccine we would need to protect the global population. This situation could lead to a public health crisis,” said Dr Marie-Paule Kieny, Director, WHO Initiative for Vaccine Research. “The Global Action Plan sets the course for what needs to be done, starting now, to increase vaccine production capacity and close the gap. In just three to five years we could begin to see results that could save many lives in case of a pandemic.” (WHO)

Several billion doses short. Billion, as in one with nine zeros after it. With all the demand, surely the market’s “invisible hand” will come to the rescue:

Relying on market-driven forces alone, it is estimated that by 2008-2009 the production of pandemic influenza vaccine will not exceed 2.34 billion doses per year. At present, the production capacity for seasonal influenza vaccine stands at 350 million doses. Such quantities fall far short of the expected demand for vaccine during an influenza pandemic when there will likely be calls to vaccinate the entire 6.7 billion world population. The anticipated shortage is, in particular, due to the expectation that a two-dose course of vaccine will be needed to protect each person.

All influenza vaccine is currently manufactured in the industrialized world. How much of this will be shared with the rest is a matter of speculation and some concern. But vaccines aren’t the only missing piece of the puzzle. If there were a vaccine, it would be the easy part of preparation. The hard part — providing the public health services that could deliver the vaccine, care for the sick, mangage the consequences of widespread absenteeism, morbidity and mortality — is no further along in most places. We are the equivalent of a billion doses behind.

WHO is warning us, once again, to get ready. The US has already burned hundreds of billions of dollars in their ill-fated Iraq debacle. Just ten billion of that, had it been invested in vaccines for the world’s population in March of 2003, would have put us much further ahead.

It’s not just money, of course. It’s the political (and moral) will to do what is right, rather than pursue immoral ends in ways that are deeply wrong. It’s not just the errors in judgements that were made in Iraq that is so disheartening, but the absolute willingness to spend vast sums of treasure and oceans of blood for projects of war, while being so stingy with public health. No lives will be saved by the Iraq mistake. Many lives would be saved by investing in public health.

Nature’s terrorist doesn’t have to take off his shoes at the airport.

Comments

  1. #1 Name
    October 24, 2006

    It’s just so bloody obvious, isn’t it, Revere? So why do *we* (after all, we’re all living in free, democratic countries) allow it to happen? Are we collectively that stupid or blind or what?

  2. #2 crfullmoon
    October 24, 2006

    Yup. ‘Fraid so, Name.

    (“Life” is what happens while you’re making other plans?)

  3. #3 LEG
    October 24, 2006

    Let’s hope the election results in November show there are enough with sense to make a difference.

  4. #4 ssal
    October 24, 2006

    Would it be feasible for a group of people to get together and form their own company (offshore, if necessary) and go ahead produce some sort of vaccine for themselves within just a few months?

    What would be the barriers?

  5. #5 revere
    October 24, 2006

    ssal: The barriers are at least technical. We don’t know how to do this, it would be prohibitively expensive and the product more than likely worthless or dangerous. This is a high capital and very tricky business. It is not straightforward.

  6. #6 ssal
    October 25, 2006

    What about a group of people getting together and trying to buy some of the new vaccine from GSK? (My current understanding is that Swissmedic has approved it and that Switzerland has just ordered enough of it for every Swiss citizen.)

  7. #7 Nancy
    October 25, 2006

    I follow GSK very closely as an offshoot of my work. The co. does not have the capacity (let alone the profit incentive–by its own admission in publicly available documents–to produce even a fraction of the world demand. In fact, according to a public disclosure by GSK a couple of quarters ago, even if every vaccine manufacturer began producing only panflu vaccine and worked 24/7, there still isn’t enough capacity to produce enough to meet the world demand within a reasonable timeframe. Vast amounts of new manufacturing facilities need to be built, and staffed, if there is to be any hope. And, even if construction were to start today, it would be at least a year before those facilities come on line. Vaccine in the foreseeable future is a pipedream.

  8. #8 ssal
    October 25, 2006

    By any chance are you the Nancy listed on the GSK Web site in an “Enquiries” section indicating that there is a “Nancy” who is a U.S. contact?